Samsung Bioepis biosimilars sales in Europe grow 7.8% - (The Korea Herald via NewsPoints Desk)

  • Sales of Samsung Bioepis' biosimilars in Europe reached 866 billion won ($795 million) last year, the drugmaker said Friday, reported The Korea Herald.

  • Samsung Bioepis, a joint venture between Biogen and Samsung Group’s biopharmaceutical unit Biologics, cited an earnings report from Biogen.

  • According to the report, sales of Samsung Bioepis’ autoimmune biosimilars Benepali, Flixabi and Imraldi grew 7.8% from a year earlier.

  • Benepali, a biosimilar of Amgen's Enbrel, is used to treat rheumatoid arthritis. Benepali’s revenue posted 524 billion won, a 0.9% decrease on-year.

  • Sales of Flixabi, used to treat Crohn’s disease, grew 43.8% on-year to 107 billion won. 

  • Meanwhile, Imraldi, a biosimilar of Humira used to treat rheumatoid arthritis and other autoimmune diseases, reached 235 billion won, up 17.6% from a year earlier.

To read more NewsPoints articles, click here.

Reference Articles